Cytotoxic T cell (CTL) assay with Keytruda (anti-PD1)



The cytotoxic T Lymphocyte (CTL) response is recognized as perhaps the most relevant functional measure that reflects cell-mediated acquired immune defense against viral infections and cancer. The CTL responses can evaluate effective antigen presentation by tumors and is a key assessment in how well a drug candidate enhances CTL responses in eradicating or killing tumors. This assay utilizes our proprietary HLA-matched CTL and tumor cell lines and is run in a 96 well format.

What is the assay setup?

  1. Co-culture tumor and CTL for 24 hours in the presence of drug candidate
  2. After 24 hours harvest the supernatants
  3. Measure cytokine release and tumor lysis

What are the study arms?

  1. CTL + Tumor+ Keytruda (anti-PD1)
  2. CTL + Tumor+ <drug candidate (per dose)>
  3. CTL + Tumor
  4. CTL + Tumor + DMSO
  5. CTL
  6. Tumor

How many doses are included?

The assay is run in a 96 well plate and can accommodate up to 40 doses of the drug candidate. Each dose is a well.

What is included the price?

  • Multiplex cytokine readouts – IL-2, IL-6, IL-4, IL-5, IL-9 IL-10, IL-13,IL-17, TNF-α, IFN-γ
  • Assay setup and methods used
  • Raw data files for cytokines

When can I expect results?

We project results are available in 2-3 weeks. We can accelerate results on a case-by-case basis. Contact us and we can work with you to accommodate your requests.

Combination arm

Include study arms in combination with Keytruda (anti-PD1)

Flow cytometry

Study expression markers on CTL and tumors in response to drug candidates.